0001193125-26-143703
SEC filingInogen, Inc. entered into a Cooperation Agreement with Kent Lake investor parties and appointed Vafa Jamali as independent Class I director effective the earlier of its 2026 annual meeting or June 15, 2026.
Inogen's Cooperation Agreement with Kent Lake parties resolves activist engagement by securing Vafa Jamali's board seat in exchange for voting alignment and a 4.99% ownership cap with broad standstill restrictions, reducing near-term governance disruption risks. Jamali, a seasoned medtech executive with CEO experience at ZimVie and leadership at Medtronic's $3B respiratory division, adds strategic expertise in portfolio optimization, growth acceleration, and profitability improvement—directly relevant to Inogen's transformation into a diversified respiratory platform. His committee roles enhance oversight in audit and compliance amid the company's focus on organic growth, product innovation, and cash generation. Compensation aligns with standard non-employee director policy, signaling no special inducements. The deal stabilizes board composition ahead of the 2026 annual meeting while limiting investor influence until early 2027.